Evaluation of hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 10, 2007, Pages 3505-3509

  Painter, George R ^a   Almond, Merrick R ^a   Trost, Lawrence C ^a   Lampert, Bernhard M ^a   Neyts, Johan ^b   De Clercq, Erik ^b   Korba, Brent E ^c   Aldern, Kathy A ^d   Beadle, James R ^d   Hostetler, Karl Y ^d  

^a Chimerix Inc   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CMX 157; ESTERASE; HEXADECYLOXYPROPYL 9 [2 (PHOSPHONOMETHOXY)PROPYL]ADENINE; LIPID; LYSOPHOSPHATIDYLCHOLINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG UPTAKE; ESTERIFICATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TARGET CELL; TECHNOLOGY;

ADENINE; ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CELL LINE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 34948857943     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00460-07     Document Type: Article

References (24)

1. Aldern, K. A., S. L. Ciesla, K. L. Winegarden, and K. Y. Hostetler. 2003. The increased antiviral activity of 1-O-hexadecyloxypropyl- cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 63:678-681.
2. Beadle, J. R., N. Rodriquez, K. A. Aldern, C. Hartline, E. Harden, E. R. Kern, and K. Y. Hostetler. 2002. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46:2381-2386.
3. Beadle, J. R., W. B. Wan, S. L. Ciesla, K. A. Keith, C. Hartline, E. R. Kern, and K. Y. Hostetler. 2006. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine (HPMPA) against cytomegalovirus and orthopoxviruses. J. Med. Chem. 49:2010-2015.
4. Bidanset, D. J., J. R. Beadle, W. B. Wan, K. Y. Hostetler, and E. R. Kern. 2004. Oral activity of ether lipid prodrugs of cidofovir against experimental human cytomegalovirus infections. J. Virol. 190:499-503.
5. Buckheit, R. W., V. Fliakas-Boltz, W. D. Decker, J. L. Roberson, T. L. Stup, C. A. Pyle, E. L. White, J. B. McMahon, M. J. Currens, M. R. Boyd, and J. P. Bader. 1995. Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res. 26:117-132.
6. Buller, R. M., G. Owens, J. Schriewer, L. Melman, J. R. Beadle, and K. Y. Hostetler. 2004. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318:474-481.
7. Choo, H., J. R. Beadle, E. R. Kern, M. N. Prichard, K. A. Keith, C. B. Hartline, J. Trahan, K. A. Aldern, B. E. Korba, and K. Y. Hostetler. 2007. Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoesters. Antimicrob. Agents Chemother. 51:611-615.
8. Ciesla, S. L., J. Trahan, K. L. Winegarden, K. A. Aldern, G. R. Painter, and K. Y. Hostetler. 2003. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 59:163-171.
9. Connelly, M. C., B. L. Robbins, and A. Fridland. 1993. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC) in Vero cells. Biochem. Pharmacol. 46:1053-1057.
10. Cundy, K. C. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogs cidofovir and adefovir. Clin. Pharmacokinet. 36:127-143.
11. De Clercq, E., and A. Holý. 2005. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4:928-940.
12. Hammond, J. L., D. Koontz, H. Z. Bazmi, J. R. Beadle, S. E. Hostetler, G. D. Kini, K. A. Aldern, D. D. Richman, K. Y. Hostetler, and J. W. Mellors. 2001. Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside resistant human immunodeficiency virus type 1 and select for resistance mutations that reverse zidovudine resistance. Antimicrob. Agents Chemother. 45:1621-1628.
13. Ho, H. T., K. L. Woods, J. J. Bronson, H. De Boeck, J. C. Martin, and M. J. M. Hitchcock. 1992. Intracellular metabolism of the antiherpesvirus agent (S)-1-[3-hydroxy-2-(phosphonyl-methoxyl)propyl]cytosine. Mol. Pharmacol. 41:197-202.
14. Holý, A. 2003. Phosphonomethoxyalkyl analogs of nucleotides. Curr. Pharm. Des. 9:2567-2592.
15. Hostetler, K. Y., K. A. Aldern, W. B. Wan, S. L. Ciesla, and J. R. Beadle. 2006. Alkoxyalkyl esters of (S)-9-[3-hydroxy-2- (phosphonomethoxy)propyl] adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 50:2857-2859.
16. Kern, E. R., D. J. Collins, W. B. Wan, J. R. Beadle, K. Y. Hostetler, and D. C. Quenelle. 2004. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48:3516-3522.
17. Kern, E. R., C. Hartline, E. Harden, K. Keith, N. Rodriguez, J. R. Beadle, and K. Y. Hostetler. 2002. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:991-995.
18. Korba, B. E., and J. L. Gerin. 1992. Use of a standardized cell culture assay to determine activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 19:55-70.
19. Korba, B. E., and G. Milman. 1991. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res. 15:217-228.
20. Ladner, S. K., M. J. Otto, C. S. Barker, K. Zaifert, G. H. Wang, J. T. Guo, C. Seeger, and R. W. King. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41:1715-1720.
21. Painter, G. R., and K. Y. Hostetler. 2004. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 22:423-427.
22. Quenelle, D. C., D. J. Collins, K. Y. Hostetler, J. R. Beadle, W. B. Wan, and E. R. Kern. 2004. Oral treatment of cowpox and vaccinia infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48:404-412.
23. Valiaeva, N., J. R. Beadle, K. A. Aldern, J. Trahan, and K. Y. Hostetler. 2006. Synthesis and antiviral evaluation of alkoxyalkyl esters of acyclic purine and pyrimidine nucleoside phosphonates against HIV-1 in vitro. Antiviral Res. 72:10-19.
24. Wan, W. B., J. R. Beadle, C. B. Hartline, E. R. Kern, S. L. Ciesla, N. Valiaeva, and K. Y. Hostetler. 2005. Comparison of the antiviral activity of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 49:656-662.